Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is among the 20 Best Performing Stocks in 2025.

Piper Sandler Maintains An Overweight rating On Arrowhead Pharmaceuticals, Inc. (ARWR)

On December 17, 2025, TheFly reported that Piper Sandler maintained its Overweight rating for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) and lifted its price objective from $70 to $100. The company has introduced Redemplo for Familial Chylomicronemia Syndrome, as stated by analyst Edward Tenthoff. Piper anticipates at least $625,000 in U.S. FCS sales in Q4 2025 and $12.3 million in 2026. The business stated that these projections could be conservative due to Redemplo’s greater potency, quarterly dosing schedule, and $60,000 lower yearly price compared to Ionis’ Tryngolza. Furthermore, Piper showed confidence that the firm will disclose positive Phase III Redemplo data in cases of severe hypertriglyceridemia in Q3 2026, with the possibility of a blockbuster label expansion in 2027.

Separately, on January 7, 2026, Morgan Stanley maintained its Equal Weight rating while increasing its price objective for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)  from $48 to $81. The firm noted early ARO-INHBE and ARO-ALK7 monotherapy data, claiming that the findings verify the fat loss objective and show prospects in obesity, which it sees as an additional value driver.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is an American biotechnology firm.

While we acknowledge the risk and potential of ARWR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARWR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None